Neurosense Therapeutics Ltd (NRSN)

$1.25 +0.02 (1.63%)
Market Cap 16.81M
Revenue (ttm) 0.00
Net Income (ttm) -10.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 215,300
Avg Vol 744,968
Day's Range N/A - N/A
Shares Out 13.67M
Stochastic %K 67%
Beta 1.61
Analysts Sell
Price Target $10.75

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 799 6183
Address:
Building B, 11 HaMenofim Street, Herzliya, Israel
Parched_Lips
Parched_Lips Oct. 4 at 11:46 PM
$NRSN
0 · Reply
Zofar
Zofar Oct. 4 at 4:55 PM
$NRSN ohh Alon keeps screwing you hhhhh thank you Alon
0 · Reply
Parched_Lips
Parched_Lips Oct. 3 at 11:36 PM
$NRSN Unfortunately ....
1 · Reply
Losingit1
Losingit1 Oct. 3 at 8:41 PM
$NRSN
0 · Reply
stevelue
stevelue Oct. 3 at 8:12 PM
$NRSN I like that our float is a tiny 25 Million....Now give us the Partnership Deal and we're Golden.....Cheers!
1 · Reply
stevelue
stevelue Oct. 3 at 8:03 PM
$NRSN somebody was quietly buying up the $1.25's today....We traded Above our average volume.....hmmm
1 · Reply
Parched_Lips
Parched_Lips Oct. 3 at 7:58 PM
$NRSN unfortunately I can say nothing but...
0 · Reply
Alexph23
Alexph23 Oct. 3 at 6:40 PM
$NRSN Will Alon deliver? That’s the question. After almost a year with a binding term shit (and not sheet, not a mistake), he already should have moved to another partner if he’d really care for patients! I finally trimmed my position today, having other stocks that are much more interesting, with more credible management. I kept a position in case it finally delivers, but it is less likely week after week after week. We are all learning from present and past mistakes. Anyway if it flies I will be more than happy with my small position. GLTE
1 · Reply
stevelue
stevelue Oct. 3 at 6:27 PM
$NRSN are we Waking up today here? Let's get that partner finalized for Phase 3...We already know the drug works! Cheers!
0 · Reply
Robertsylvan
Robertsylvan Oct. 3 at 6:17 PM
$NRSN come team NRSN. We know you had a binding term sheet. Let’s get this negotiation wrapped up or move to new partner. Let’s get r done.
0 · Reply
Latest News on NRSN
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Sep 10, 2025, 2:30 PM EDT - 24 days ago

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Sep 4, 2025, 8:49 AM EDT - 4 weeks ago

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NeuroSense Provides Business Update and Progress for the First Half of 2025

Aug 1, 2025, 9:00 AM EDT - 2 months ago

NeuroSense Provides Business Update and Progress for the First Half of 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Jul 22, 2025, 8:42 AM EDT - 2 months ago

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025, 3:08 PM EDT - 5 months ago

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025, 8:45 AM EDT - 5 months ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

Apr 24, 2025, 9:09 AM EDT - 5 months ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Apr 9, 2025, 8:30 AM EDT - 6 months ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

Apr 7, 2025, 5:14 PM EDT - 6 months ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Apr 4, 2025, 9:10 AM EDT - 6 months ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Mar 17, 2025, 8:30 AM EDT - 7 months ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

Jan 6, 2025, 9:00 AM EST - 9 months ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Dec 23, 2024, 9:00 AM EST - 10 months ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

Dec 18, 2024, 10:25 AM EST - 10 months ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Dec 11, 2024, 9:25 AM EST - 10 months ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

Dec 4, 2024, 8:30 AM EST - 10 months ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

Dec 2, 2024, 8:30 AM EST - 10 months ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Nov 21, 2024, 9:20 AM EST - 11 months ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Oct 28, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Oct 24, 2024, 8:30 AM EDT - 1 year ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Oct 15, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

Oct 9, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

Oct 7, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

Sep 24, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Sep 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Aug 30, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

Aug 7, 2024, 2:00 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

Aug 1, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Jul 9, 2024, 9:27 AM EDT - 1 year ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

This cheap biotech offers investors a play on ALS if trial data continues to impress

Jul 2, 2024, 12:34 PM EDT - 1 year ago

This cheap biotech offers investors a play on ALS if trial data continues to impress

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

Jul 1, 2024, 8:00 AM EDT - 1 year ago

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Jun 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

Jun 21, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

May 20, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

May 14, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

May 7, 2024, 8:45 AM EDT - 1 year ago

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces First Quarter 2024 Business Update

May 2, 2024, 9:19 AM EDT - 1 year ago

NeuroSense Announces First Quarter 2024 Business Update

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

Apr 22, 2024, 8:30 AM EDT - 1 year ago

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

Apr 18, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

Apr 12, 2024, 8:30 AM EDT - 1 year ago

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

Apr 10, 2024, 7:16 PM EDT - 1 year ago

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

Apr 9, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

Apr 5, 2024, 9:29 AM EDT - 1 year ago

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

Feb 21, 2024, 8:30 AM EST - 1 year ago

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

Jan 30, 2024, 8:30 AM EST - 1 year ago

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

BIIB

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

Jan 9, 2024, 8:45 AM EST - 1 year ago

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Dec 27, 2023, 5:00 PM EST - 1 year ago

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

Dec 14, 2023, 9:24 AM EST - 1 year ago

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Dec 5, 2023, 8:00 AM EST - 1 year ago

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Parched_Lips
Parched_Lips Oct. 4 at 11:46 PM
$NRSN
0 · Reply
Zofar
Zofar Oct. 4 at 4:55 PM
$NRSN ohh Alon keeps screwing you hhhhh thank you Alon
0 · Reply
Parched_Lips
Parched_Lips Oct. 3 at 11:36 PM
$NRSN Unfortunately ....
1 · Reply
Losingit1
Losingit1 Oct. 3 at 8:41 PM
$NRSN
0 · Reply
stevelue
stevelue Oct. 3 at 8:12 PM
$NRSN I like that our float is a tiny 25 Million....Now give us the Partnership Deal and we're Golden.....Cheers!
1 · Reply
stevelue
stevelue Oct. 3 at 8:03 PM
$NRSN somebody was quietly buying up the $1.25's today....We traded Above our average volume.....hmmm
1 · Reply
Parched_Lips
Parched_Lips Oct. 3 at 7:58 PM
$NRSN unfortunately I can say nothing but...
0 · Reply
Alexph23
Alexph23 Oct. 3 at 6:40 PM
$NRSN Will Alon deliver? That’s the question. After almost a year with a binding term shit (and not sheet, not a mistake), he already should have moved to another partner if he’d really care for patients! I finally trimmed my position today, having other stocks that are much more interesting, with more credible management. I kept a position in case it finally delivers, but it is less likely week after week after week. We are all learning from present and past mistakes. Anyway if it flies I will be more than happy with my small position. GLTE
1 · Reply
stevelue
stevelue Oct. 3 at 6:27 PM
$NRSN are we Waking up today here? Let's get that partner finalized for Phase 3...We already know the drug works! Cheers!
0 · Reply
Robertsylvan
Robertsylvan Oct. 3 at 6:17 PM
$NRSN come team NRSN. We know you had a binding term sheet. Let’s get this negotiation wrapped up or move to new partner. Let’s get r done.
0 · Reply
Speculator2
Speculator2 Oct. 3 at 5:33 PM
$NRSN Scenario #1: They eventually and finally secure a partnership, and they launch their phase 3. Scenario #2: They cannot secure financing and declare they just have to abandon the whole project due to lack of funding. PrimeC freezes between stage 2 and 3. Scenario #3: They sell the whole company and assets to a third party that takes over from here. And other scenario?
1 · Reply
Parched_Lips
Parched_Lips Oct. 3 at 4:20 PM
$NRSN you want to know the truth? It would wipe out every investor here. Alon is the biggest bullshitter in biotech history imho
0 · Reply
Parched_Lips
Parched_Lips Oct. 3 at 3:28 PM
$NRSN If they ever had a binding term sheet it would have been with TEVA. However an even bigger problem arises as TEVA is also an Israeli company. Take whay you may from it but NRSN got played by their own imho
0 · Reply
Stekli27
Stekli27 Oct. 3 at 2:56 PM
$KOD $NRSN As I said before, I’m not changing my mind. Already made 16k+ since April with Kodiak and now holding 10k shares of $NRSN – for me it’s a must have. Risk is there, but the upside is even bigger. It’s a coin flip, and I’m willing to take it. Cheers
0 · Reply
Parched_Lips
Parched_Lips Oct. 3 at 2:45 PM
$NRSN nearly a whole year. You could have bought RGTI at 73 cents a year ago today. Share price is $38 now.
0 · Reply
Parched_Lips
Parched_Lips Oct. 3 at 2:26 PM
$NRSN The only point here is everyone here has been fooled. Its a sad ending but you cant expect anything different from these off shore bios especially Israeli. They are notorious for this sort of thing. Improper filings, less regulations, nefarious tweets pumping their stocks and carrot dangling are all hallmarks of a scam. I believe some things said here but the vast majority of things said are inherently designed to keep investors on the line. Unfortunately so many here have been duped into believing there was a partnership in the works. I hope you can all see the reality of the situation as Unfortunate as it is 😔
0 · Reply
Parched_Lips
Parched_Lips Oct. 3 at 2:17 PM
$NRSN I thought that too but that last 500 k is allready burned through
0 · Reply
Alexph23
Alexph23 Oct. 3 at 2:10 PM
$NRSN I almost sold most of my shares left, but I still can’t think anything will happen in the coming weeks… Who the hell would buy a stock at 40% premium without knowing its gonna ride much higher? 500 000$ is not much so they can’t surf much longer on it. I give it 2 more weeks before slashing my position again. Patience is one thing, being stupid is another.
3 · Reply
Parched_Lips
Parched_Lips Oct. 3 at 1:58 PM
$NRSN 👀
0 · Reply
Parched_Lips
Parched_Lips Oct. 3 at 1:56 PM
$NRSN Alon is that you?
0 · Reply
bourne86
bourne86 Oct. 3 at 1:56 PM
$NRSN and so the waiting game continues
0 · Reply
Parched_Lips
Parched_Lips Oct. 3 at 1:55 PM
$NRSN if its news today it aint gonna be good news as its friday
0 · Reply